These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38900374)

  • 21. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
    Zhou D; Li Z; Bai X
    Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic assessment of chemokine ligand bias at the human chemokine receptor CXCR2 indicates G protein bias over β-arrestin recruitment and receptor internalization.
    Boon K; Vanalken N; Szpakowska M; Chevigné A; Schols D; Van Loy T
    Cell Commun Signal; 2024 Jan; 22(1):43. PubMed ID: 38233929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.
    Cui D; Zhao Y; Xu J
    Cancer Biol Ther; 2019; 20(5):608-616. PubMed ID: 30404567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Constitutive and treatment-induced CXCL8-signalling selectively modulates the efficacy of anti-metabolite therapeutics in metastatic prostate cancer.
    Wilson C; Maxwell PJ; Longley DB; Wilson RH; Johnston PG; Waugh DJ
    PLoS One; 2012; 7(5):e36545. PubMed ID: 22590561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probiotics improve re-epithelialization of scratches infected by Porphyromonas gingivalis through up-regulating CXCL8-CXCR1/CXCR2 axis.
    Albuquerque-Souza E; Ishikawa KH; Amado PP; Nicoli JR; Holzhausen M; Mayer MPA
    Anaerobe; 2021 Dec; 72():102458. PubMed ID: 34547426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of the CXCL8/CXCR1/R2 signalling axis in patients with invasive breast cancer.
    Stępień S; Smycz-Kubańska M; Kruszniewska-Rajs C; Gola JM; Kabut J; Olczyk P; Mielczarek-Palacz A
    Oncol Lett; 2024 Jun; 27(6):260. PubMed ID: 38646491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
    De Soyza A; Pavord I; Elborn JS; Smith D; Wray H; Puu M; Larsson B; Stockley R
    Eur Respir J; 2015 Oct; 46(4):1021-32. PubMed ID: 26341987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-8, but not the Related Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem Cells.
    Liotti F; Collina F; Pone E; La Sala L; Franco R; Prevete N; Melillo RM
    Stem Cells; 2017 Jan; 35(1):135-146. PubMed ID: 27577959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fine-Tuning of GPCR-Chemokine Interactions. Design and Identification of Chemokine Analogues as Receptor Agonists, Biased Agonists, and Antagonists.
    Navarro J
    Biochemistry; 2019 Mar; 58(10):1432-1439. PubMed ID: 30726064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers.
    Cullberg M; Arfvidsson C; Larsson B; Malmgren A; Mitchell P; Wählby Hamrén U; Wray H
    Drugs R D; 2018 Jun; 18(2):149-159. PubMed ID: 29856004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer.
    Ghallab AM; Eissa RA; El Tayebi HM
    Front Pharmacol; 2022; 13():862125. PubMed ID: 35517812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonists.
    Xue D; Chen W; Neamati N
    Eur J Med Chem; 2020 Oct; 204():112387. PubMed ID: 32829163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activated CXCL5-CXCR2 axis promotes the migration, invasion and EMT of papillary thyroid carcinoma cells via modulation of β-catenin pathway.
    Cui D; Zhao Y; Xu J
    Biochimie; 2018 May; 148():1-11. PubMed ID: 29471001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway.
    Sturm A; Baumgart DC; d'Heureuse JH; Hotz A; Wiedenmann B; Dignass AU
    Cytokine; 2005 Jan; 29(1):42-8. PubMed ID: 15579377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
    Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Syntheses of a radiolabelled CXCR2 antagonist AZD5069 and its major human metabolite.
    Hickey MJ; Allen PH; Caffrey M; Hansen P; Kingston LP; Wilkinson DJ
    J Labelled Comp Radiopharm; 2016 Sep; 59(11):432-8. PubMed ID: 27461061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
    Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
    Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined effects of CXCL8 and CXCR2 gene polymorphisms on susceptibility to systemic sclerosis.
    Salim PH; Jobim M; Bredemeier M; Chies JA; Brenol JC; Jobim LF; Xavier RM
    Cytokine; 2012 Nov; 60(2):473-7. PubMed ID: 22763041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXCL8 Promotes Endothelial-to-Mesenchymal Transition of Endothelial Cells and Protects Cells from Erastin-Induced Ferroptosis via CXCR2-Mediated Activation of the NF-κB Signaling Pathway.
    Ji HZ; Chen L; Ren M; Li S; Liu TY; Chen HJ; Yu HH; Sun Y
    Pharmaceuticals (Basel); 2023 Aug; 16(9):. PubMed ID: 37765018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.
    Maxwell PJ; Neisen J; Messenger J; Waugh DJ
    Oncotarget; 2014 Jul; 5(13):4895-908. PubMed ID: 24970800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.